Greenwich LifeSciences (GLSI) Receives a Buy from H.C. Wainwright

Stock Market

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Greenwich LifeSciences (GLSIResearch Report) today and set a price target of $78.00. The company’s shares closed last Monday at $32.11.

According to, Chen is a 5-star analyst with an average return of 29.5% and a 38.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Greenwich LifeSciences with a $78.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

You Might Like

Greenwich LifeSciences’ market cap is currently $421.4M and has a P/E ratio of -105.60. The company has a Price to Book ratio of 15.62.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Greenwich LifeSciences Inc is a clinical stage bio-pharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients.

Read More on GLSI:

Articles You May Like

Leadership turmoil at Idaho community college leads to negative outlook
5 questions for CFP Board CEO Kevin Keller about enforcement
Stocks making the biggest moves premarket: Delta Air Lines, Moderna, Virgin Orbit and others
Rate hike concerns abound, but munis steady ahead of $7B calendar
Infrastructure Act’s bridge money begins to flow to states

Leave a Reply

Your email address will not be published. Required fields are marked *